EQT sold Aldevron for $9.6bn just 22 months after buying the maker of mRNA vaccine components for $3.4bn.
The scale of the firm’s Belron deal set the bar high for GP-led single asset deals. And it’s clear as glass that GPs will be looking to beat it.
Accel-KKR saw that Seequent’s geological scanning software could dig much deeper than first thought, with far more applications possible.
TaylorMade was buried in the bunker until KPS made a brilliant sand save.
Scalpel! Francisco’s carve-out of Capsule Technologies, which provides patient monitoring and medical device integration, was just what the doctor ordered.
“There are still a lot of disruptions in the supply chain," said STG Logistics CEO Paul Svindland. "The demand to move goods is greater than the supply of capacity out there.”
Blair is one of several banks and financial advisers thinking about adding secondaries capabilities.
“What tends to unite our themes or strategies is the healthcare triple aim – which refers to a company that will simultaneously work to improve healthcare outcomes, improve member experience and lower cost."
Will a new rulemaking proposal from the SEC slow down the use of blank-check companies, which raised a record $162.5bn through 613 IPOs last year?
"My real ambition is to see oil and gas companies like Civitas added back to ESG funds," Dell said.